



Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Indacaterol-glycopyrronium
Brand Name	Ultibro® Breezhaler®
Dosage Form	110 mcg/50 mcg
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Submission Review	New Submission
Use Reviewed	Chronic obstructive pulmonary disease (COPD)
Common Drug Review (CDR)	Yes. CDR recommended to List with criteria . Visit the CDR website for more details: www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0369_Ultibro%20Breezhaler_Jan30_2015.pdf
Drug Benefit Council (DBC)	DBC met on January 12, 2015. DBC considered various inputs including: general inputs (e.g. review completed by the CDR including clinical evidence and pharmacoeconomic reports), and input from a specialist and a general practitioner. No Patient Input Questionnaire responses were received through Your Voice.
Drug Coverage Decision	Limited Coverage benefit. Access the indacaterol-glycopyrronium criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	June 2, 2015
Reasons	<p>Drug coverage decision is consistent with the DBC recommendation.</p> <ul style="list-style-type: none"> The drug was similar to or demonstrated some advantage over combinations of formoterol-tiotropium and fluticasone propionate-salmeterol with respect to efficacy and quality of life. Based on economic considerations and the submitted product price, the drug is cost-effective and offers value for money compared to existing drugs for the treatment of COPD.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.